BioCentury
ARTICLE | Company News

Caladrius Biosciences, AiVita Biomedical deal

June 6, 2016 7:00 AM UTC

Caladrius granted AiVita exclusive, worldwide rights to tumor cell/dendritic cell technology to treat ovarian cancer. Caladrius is eligible for undisclosed development milestones and royalties. AiVita...